Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-04-30T16:24:49.138Z Has data issue: false hasContentIssue false

Chap. 34 - BOTOX: HOW WE DO IT

from PART THREE - FILLERS AND NEUROTOXINS

Published online by Cambridge University Press:  06 July 2010

Sorin Eremia
Affiliation:
University of California, Los Angeles, School of Medicine
Get access

Summary

Botulinum toxin is a powerful medication that has been used to treat various conditions in humans for several decades. In the last few years, there has been an explosion in the use of this drug for cosmetic purposes. Millions have benefited from the therapeutic effects of botulinum toxin, with very few patients experiencing adverse effects. In this chapter, we will discuss the various techniques and therapeutic uses of botulinum toxin in the field of cosmetic dermatology.

MECHANISMS OF ACTION

The mechanism of action of botulinum toxin (BTX) has been well established (Sakaguchi 1983; Carruthers and Carruthers 1992; Keen et al. 1994; Hambleton 1992). Protein interactions at the neuromuscular junction prevent the release of acetylcholine. There are seven known antigenically distinct serotypes of BTX (A–G). The most widely used and studied is botulinum toxin type A (BTX-A). This protein irreversibly binds and cleaves the SNAP-25 protein. There are currently two available preparations of BTX-A on the U.S. market: Botox and Dysport. Botulinum toxin type B (BTX-B) binds to synaptobrevin. BTX-B is available commercially as Myobloc. The temporary nature of therapeutic BTX therapy is due to axonal sprouting at the motor end plate of the neuromuscular junction as well as the development of extrajunctional acetylcholine receptors (de Paiva et al. 1999). This occurs over several months after BTX therapy.

COSMETIC USE

Cosmetic BTX treatments have become one of the most common nonsurgical procedures performed by dermatologists and plastic surgeons.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bhatia, KP, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J. Neurol. Neurosurg. Psychiatry 1999;67:90–3.CrossRefGoogle ScholarPubMed
BOTOX Cosmetic [package insert]. Irvine, CA: Allergan Inc.; 2005.
Carruthers, JDA, Carruthers, JA. Treatment of glabellar frown lines with C botulinum-A exotoxin. J. Dermatol. Surg. Oncol. 1992;18:17–21.CrossRefGoogle ScholarPubMed
Paiva, A, Meunier, FA, Molgo, J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. U. S. A. 1999;96:3200–5.CrossRefGoogle ScholarPubMed
Hambleton, P.Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J. Neurol. 1992;239:16–20.CrossRefGoogle ScholarPubMed
Heckmann, M, Ceballos-Baumann, AO, Plewig, G. Botulinum toxin A for axillary hyperhidrosis. N. Engl. J. Med. 2001;344:488–93.CrossRefGoogle ScholarPubMed
Keen, M, Blitzer, A, Aviv, J, et al. Botulinum toxin A therapy for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast. Reconstr. Surg. 1994;94:94–9.CrossRefGoogle ScholarPubMed
Lowe, PL, Cerdan-Sanz, S, Lowe, NJ. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol. Surg. 2003;29:545–8.Google ScholarPubMed
Naumann, M, Lowe, NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. Br. Med. J. 2001;323:596–9.CrossRefGoogle ScholarPubMed
Pierard, GE, Lapiere, CM. The microanatomical basis of facial frown lines. Arch. Dermatol. 1989;125:1090–2.CrossRefGoogle ScholarPubMed
Sadick, NS, Matarasso, SL. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol. Clin. 2004;22:221–6.CrossRefGoogle Scholar
Sakaguchi, G.Clostridium botulinum toxins. Pharmacol. Ther. 1983;19:165–94.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×